Similar to the ADAURA trial for EGFR + NSCLC, for patients who have undergone radical surgery for IB (T > 4 cm)-IIIA (7th TNM) ALK+ NSCLC, three randomized phase III trials, ALCHEMIST, ALINA, and NCT05341583, have been carried out to rule out the efficacy of crizotinib, alectinib, amd ensartinib, respectively [106]. This evidence concerns the gene ALK and non-small cell lung carcinoma.